Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Head and Neck Cancer ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

The latest pharma company to make a move for an mRNA specialist is Germany's Merck KGaA, which has offered a $780 million cash buyout to US biotech Exelead. Unlike other recent deals however the ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

RAHWAY, N.J. - Merck (NYSE: MRK) and its subsidiary EyeBio have announced the commencement of the BRUNELLO trial, a pivotal study evaluating the efficacy and safety of the investigational drug ...

In the first and fifth paragraphs of release dated Aug. 14, 2024, investor company name should read: Merck KGaA, Darmstadt, ...

BERKELEY, Calif., September 03, 2024--(BUSINESS WIRE)--In the first and fifth paragraphs of release dated Aug. 14, 2024, investor company name should read: Merck KGaA, Darmstadt, Germany (instead ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

It is currently being tested in combination with Merck & Co’s Keytruda. The two companies completed a successful phase 2 study to evaluate intra-tumoral administration of BO-112 and pembrolizumab in ...

MB310 will be evaluated for treating ulcerative colitis and the candidate that interests us the most today, MB097 will be evaluated in combination with Merck’s ICI Keytruda against advanced melanoma.